Molecular Dx Labs’ Concerns Shift To Coverage Issues With Release Of Interim Medicare Payment Amounts

03 Jun 2013

Now that CMS has posted the interim payment amounts for more than 100 new molecular pathology codes, industry is concerned whether the tests will be covered at all.

Labs that run molecular diagnostic tests are not only worried about getting short-changed on payment for the tests by some Medicare Part B contractors, but that the tests will not be covered at all.

“A growing concern to us I think, or of equal concern with the prices, is the coverage issue,” JoAnne Glisson,...